摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,7-二甲氧基-1H-吡咯[2,3-C]吡啶 | 452296-79-6

中文名称
4,7-二甲氧基-1H-吡咯[2,3-C]吡啶
中文别名
4,7-二甲氧基-1H-吡咯并[2,3-C]吡啶
英文名称
4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridine
英文别名
4,7-dimethoxy-6-azaindole
4,7-二甲氧基-1H-吡咯[2,3-C]吡啶化学式
CAS
452296-79-6
化学式
C9H10N2O2
mdl
MFCD09909835
分子量
178.191
InChiKey
XQAVWTMXLIRALT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    352℃
  • 密度:
    1.245
  • 闪点:
    129℃

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.222
  • 拓扑面积:
    47.1
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:48d8a9bd3b8a89c7fe0cf27ea8d03791
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4,7-二甲氧基-1H-吡咯[2,3-C]吡啶盐酸 作用下, 以 N-甲基吡咯烷酮 为溶剂, 反应 6.0h, 以81%的产率得到7-羟基-4-甲氧基-6-氮杂吲哚
    参考文献:
    名称:
    Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacement
    摘要:
    With the emergence of drug-resistant strains and the cumulative toxicities associated with current therapies, demand remains for new inhibitors of HIV-1 replication. The inhibition of HIV-1 entry is an attractive, yet underexploited therapeutic approach with implications for salvage and preexposure prophylactic regimens, as well as topical microbicides. Using the combination of a field-derived bioactive conformation template to perform virtual screening and iterative bioisosteric replacements, coupled with in silico predictions of absorption, distribution, metabolism, and excretion, we have identified new leads for HIV-1 entry inhibitors. (C) 2014 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2014.10.027
  • 作为产物:
    描述:
    5-溴-2-氯-3-硝基吡啶氢化钾 作用下, 以 四氢呋喃甲苯 为溶剂, 反应 15.0h, 生成 4,7-二甲氧基-1H-吡咯[2,3-C]吡啶
    参考文献:
    名称:
    Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacement
    摘要:
    With the emergence of drug-resistant strains and the cumulative toxicities associated with current therapies, demand remains for new inhibitors of HIV-1 replication. The inhibition of HIV-1 entry is an attractive, yet underexploited therapeutic approach with implications for salvage and preexposure prophylactic regimens, as well as topical microbicides. Using the combination of a field-derived bioactive conformation template to perform virtual screening and iterative bioisosteric replacements, coupled with in silico predictions of absorption, distribution, metabolism, and excretion, we have identified new leads for HIV-1 entry inhibitors. (C) 2014 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2014.10.027
点击查看最新优质反应信息

文献信息

  • DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS
    申请人:Wang Tao
    公开号:US20070249579A1
    公开(公告)日:2007-10-25
    This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.
    本公开提供具有药物和生物影响特性的化合物,它们的药物组合物和使用方法。具体而言,该公开涉及具有独特抗病毒活性的二酮哌嗪和哌啶衍生物。更具体地说,本公开涉及用于治疗艾滋病毒和艾滋病的化合物。
  • Prodrugs of piperazine and substituted piperidine antiviral agents
    申请人:Ueda Yasutsugu
    公开号:US20050209246A1
    公开(公告)日:2005-09-22
    This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R 1 does not exist; W is C or N with the proviso that when W is N, R 2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C 1 -C 6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
    这项发明提供了前药化合物I,其药物组成物以及它们在治疗HIV感染中的用途。 其中: X为C或N,但当X为N时,R1不存在; W为C或N,但当W为N时,R2不存在;V为C;E为氢或其药用可接受盐;以及 Y从以下组中选择: 此外,这项发明提供了制备前药化合物I的有用中间体化合物II。 其中: L和M独立地选自C1-C6烷基,苯基,苯甲基,三烷基硅基,-2,2,2-三氯乙氧基和2-三甲基硅基乙氧基的组。
  • Method of preparation of azaindole derivatives
    申请人:Liu Wansheng
    公开号:US20070032503A1
    公开(公告)日:2007-02-08
    A method of preparing azaindole compounds for antiviral use having the formula
    一种制备用于抗病毒的吡唑吲哚化合物的方法,其化学式为
  • [EN] DIKETO AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS<br/>[FR] DICÉTO-AZOLOPIPÉRIDINES ET AZOLOPIPÉRAZINES EN TANT QU'AGENTS ANTI-VIH
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2009158394A1
    公开(公告)日:2009-12-30
    Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketo fused azolopiperidine and azolopiperazine derivatives that possess unique antiviral activity are provided. These compounds are useful the treatment of HIV and AIDS.
    具有药物和生物影响特性的化合物,其药物组合物和使用方法已经列出。具体来说,提供了具有独特抗病毒活性的二酮融合的咪唑哌啶和咪唑哌嗪衍生物。这些化合物对治疗艾滋病毒和艾滋病非常有用。
  • 4-Squarylpiperazine Derivatives as Antiviral Agents
    申请人:Bachand Carol
    公开号:US20070249624A1
    公开(公告)日:2007-10-25
    This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with 4-squarylpiperazine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.
    本公开提供具有药物和生物影响特性的化合物,它们的药物组合物和使用方法。具体而言,该公开涉及具有独特抗病毒活性的4-四氢喹啉基哌嗪衍生物。更具体地说,本公开涉及用于治疗艾滋病毒和艾滋病的化合物。
查看更多

同类化合物

(4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 骆驼蓬酸 顺-六氢-1H-吡咯并[3,2-B]吡啶-4(2H)-羧酸叔丁基酯 螺哌啶-4,3’-3H吡咯并[2,3-b]吡啶-2’(1’H)-酮 螺[哌啶-4,3'-吡咯并[2,3-B]吡啶]-2'(1'H)-酮盐酸盐 莫西沙星杂质69 苹果酸法米替尼 苯乙胺,a,4-二甲基-b-苯基- 苄基-11氢吡咯并[3,4-B]吡啶 罗沙布林 甲基6-甲酰基-1-甲基-1H-吡咯并[3,2-b]吡啶-2-羧酸酯 甲基5-氰基-1H-吡咯并[2,3-b]吡啶-2-羧酸酯 甲基1H-吡咯并[2,3-B]吡啶-5-甲酸酯 甲基-1-甲氧基-4-吡咯并[3,2-c]吡啶 甲基 5-硝基-1H-吡咯并[2,3-B]吡啶-2-羧酸 环戊二烯并[4,5]吡咯并[2,3-B]吡啶,5,6,7,8-四氢 氧代-(1H-吡咯并[2,3-b]吡啶-3-基)-乙酸甲酯 培西达替尼盐酸盐 培西达替尼 吲嗪 吲哚嗪-6-羧酸乙酯 吲哚嗪-3-甲腈 吲哚嗪-2-羧酸甲酯 吲哚嗪-2-羧酸 叔丁基八氢-1H-吡咯并[2,3-c]吡啶-6-羧酸盐 叔丁基5-溴-7-氯-3-碘-1H-吡咯并[2,3-c]吡啶-1-羧酸盐 叔丁基5-溴-7-氯-1H-吡咯并[2,3-c]吡啶-1-羧酸盐 叔丁基3-甲酰基-5-甲基-1H-吡咯并[2,3-b]吡啶-1-羧酸盐 叔丁基3-(3-羟丙基-1-炔基)-5-甲基-1H-吡咯并[2,3-b]吡啶-1-羧酸盐 叔丁基(5-甲基-1H-吡咯并[2,3-b]吡啶-3-基)氨基甲酸酯 叔丁基((5-氟代-1H-吡咯并[2,3-b]吡啶-4-基)甲基氨基甲酸酯 反式-六氢-1H-吡咯并[3,4-C]吡啶-5(6H)-羧酸叔丁酯 化合物 T28221 八氢吡咯并[3.4-b]吡啶-1-羧酸叔丁酯 八氢吡咯并[3,4-b]吡啶 八氢-吡咯[3,4-C]吡啶-2-甲酸叔丁酯 八氢-6-(苯基甲基)-1H-吡咯并[3,4-b]吡啶-1-羧酸 1,1-二甲基乙酯 八氢-1H-吡咯并[3,4-C]吡啶 二苯基(吡咯并[2,3-b]吡啶-1-基)膦 二乙基1H-吡咯并[2,3B]吡啶-2,6-二甲酸基酯 乙基7-氯-3-甲基-1H-吡咯并[3,2-b]吡啶-2-甲酸基酯 乙基7-氮杂吲哚-4-羧酸酯 乙基4-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-吡咯并[2,3-b]吡啶-2-羧酸酯 乙基3-氨基-2-吲嗪羧酸酯 乙基1-乙基-1H-吡咯并[3,2-c]吡啶-6-羧酸酯 中氮茚-7-羧酸甲酯 中氮茚-6-羧酸 中氮茚-1-甲酸甲酯 中氮茚-1-甲酸 中氮茚,1-[[4-(3-溴丙氧基)苯基]磺酰]-2-乙基-